GSK will contribute providing the Industry Sponsor point of view in Clinical Research. Pharmaceutical Industry accounts for a large percentage of the clinical trials conducted in EU and therefore the private pharmaceutical experiencie and perspective can help to better understand the current situation and to facilitate adoption of the new guidelines resulting of this project in the future. As an Innovative Industry looking for new treatments, GSK SA works in partnership with Health Institutions, Physicians, nurses, RECs and Authorities to develop new drugs and vaccines to cover unmet medical and public health needs. GSK will take part in all the project WPs with its highest dedication in WP3.

Olga Maria Martinez-Casares is head of clinical research strategy, clinical development early phases, and patient advocacy in the Medical Department of GSK.

BSc in Pharmacy from UAH in Spain and MSc in Direction of Research, Development and Innovation in Health Sciences from the National Health Research Institute Carlos III in Spain. She has wide experience in Clinical Research and hold different positions within the medical department in GlaxoSmithKline Spain, leading team in the CVM Therapy Area for several years and being the Head of Clinical Research Strategy, External Engagement and Patient Advocacy until 2017. She has global experience as Quality and Capability Manager working with more than 20 countries worldwide. She started and led the TransCelerate Country network in Spain and since 2020 Co-leads the eConsent workstream.  Currently, she is the Risk Management Director for EU and Emerging Markets within the Global Clinical Operations department in GSK s.

Email: olga.martinez-casares@gsk.com

M. REYES BOCETA MUÑOZ

Clinical Operations Head Spain, Development R&D in GSK.  She is BSc in Pharmacy and bachelor thesis on Biochemistry from UCM. She has held different positions within Clinical Operations, as project leader, clinical operations manager, delivering Vaccines PhI-IV and Epidemiological studies across portfolio in a wide range of medical areas, targeting all age groups in healthy and immunocompromised patients. She has a wide experience in clinical development of different assets, including leadership in clinical research working groups at local and international level. 

Email: reyes.boceta-munoz@gsk.com

ELENA LOPEZ SANTOS

Senior Project Manager at the GSK DDW in TresCantos. She has acted as project manager (appointed by Coordinator) in charge of the administrative and financial management in several EU funded consortiums. She is also program manager at the COFUND-Tres Cantos Open Lab Fellowship Scheme and invited evaluator expert by the EC.

Email: maria-elena.s.lopez-santos@gsk.com

FRANCISCO JAVIER RUBIO POMAR

Senior Project Manager at the GSK Medicines Development Center in Madrid-TresCantos, a Research Centre for developing new drugs against Diseases of the Developing World (DDW) that operates in an open collaborative scheme. He has participated in +10 successful EU-Funded proposals, and is actively involved in the promotion and implementation EC Marie Sklodowska Curie, and RTD-Euraxess actions.

Email: francisco-javier.p.rubio-pomar@gsk.com

MARIA CUBILLO DIAZ-VALDES

Graduate degree in Pharmacy and Biotechnology (European University of Madrid), and post-graduate diploma in Biotechnology Management (University of California Riverside). She began her professional career in the Pharmaceutical industry in the field of Clinical Research, monitoring Oncology clinical trials. After that, she participated in i-Consent project collaborating and representing the pharma industry input. A project funded by the European programme Horizon2020 formed by a multistakeholder and multicultural consortium of partners from academia, public health, patient organizations, clinicians, investigators and private sector. Now she is a Clinical Research Associate (CRA) working monitoring vaccines clinical trials focusing on healthy population and vulnerable population in multiple therapy areas. 

Email: maria.x.cubillo@gsk.com